AR080029A1 - Composicion de microburbujas que comprende un adn plasmidico que codifica un factor de crecimiento del endotelio vascular humano - Google Patents

Composicion de microburbujas que comprende un adn plasmidico que codifica un factor de crecimiento del endotelio vascular humano

Info

Publication number
AR080029A1
AR080029A1 ARP110100254A ARP110100254A AR080029A1 AR 080029 A1 AR080029 A1 AR 080029A1 AR P110100254 A ARP110100254 A AR P110100254A AR P110100254 A ARP110100254 A AR P110100254A AR 080029 A1 AR080029 A1 AR 080029A1
Authority
AR
Argentina
Prior art keywords
liver
hvegf
transplanted
islet
cells
Prior art date
Application number
ARP110100254A
Other languages
English (en)
Inventor
Shinich Matsumoto
Hirofumi Noguchi
Masayuki Shimoda
Paul A Grayburn
Shuyuan Chen
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of AR080029A1 publication Critical patent/AR080029A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)

Abstract

Método de transferencia de genes mediada por ultrasonido denominado Destruccion de Microburbujas de Ultrasonido Dirigida [Ultrasound Targeted Microbubble Destruction] (UTMD) para la administracion del gen del factor de crecimiento del endotelio vascular humano (hVEGF) en islotes transplantados y tejidos circundantes. La administracion del hVEGF promueve la revascularizacion y la sobrevida de los islotes. Los inventores transplantaron primero islotes humanos en el hígado de ratones desnudos diabéticos seguido por induccion de vectores plasmídicos no virales que codifican al gen del hVEGF o de la proteína fluorescente verde (GFP) en el hígado huésped mediante UTMD. También se efectuo un transplante sin administracion de genes como control. Se evaluaron los niveles de glucosa en sangre, insulina humana sérica y péptido C, así como la revascularizacion en los injertos de islotes. Los hallazgos del método de la presente indicaron que la administracion del gen hVEGF en el hígado huésped usando UTMD promovía la revascularizacion de los islotes después del transplante de islotes mejoraron el restablecimiento de la euglucemia. Reivindicacion 1: Una composicion para la destruccion de microburbujas por ultrasonido dirigida (UTMD) en una o más células hepáticas, un hígado o una célula de islote transplantada en el hígado que comprende: uno o más complejos de microburbujas con ADN plasmídico (ADNp) en liposomas pre-ensamblados, en donde la microburbuja comprende una cubierta de lípidos que encierra un gas y un ADNp que comprende una secuencia de un promotor constitutivo o una secuencia de un promotor inducible ligada operativamente a un factor de crecimiento del endotelio vascular humano (hVEGF), en donde la ruptura por ultrasonido de dichas una o más microburbujas en dichas una o más células hepáticas, hígado o células transplantadas en el hígado permite administrar el ADNp en dichas una o más células hepáticas, hígado o células de islotes transplantadas en el hígado en la ubicacion de la ruptura por ultrasonido, lo cual permite expresar el hVEGF, en donde la composicion mejora la eficacia de dichas una o más células de islotes transplantadas.
ARP110100254A 2010-01-27 2011-01-26 Composicion de microburbujas que comprende un adn plasmidico que codifica un factor de crecimiento del endotelio vascular humano AR080029A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29882410P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
AR080029A1 true AR080029A1 (es) 2012-03-07

Family

ID=44309134

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100254A AR080029A1 (es) 2010-01-27 2011-01-26 Composicion de microburbujas que comprende un adn plasmidico que codifica un factor de crecimiento del endotelio vascular humano

Country Status (4)

Country Link
US (1) US20110182979A1 (es)
AR (1) AR080029A1 (es)
TW (1) TW201139673A (es)
WO (1) WO2011094352A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
WO2015070050A1 (en) 2013-11-08 2015-05-14 Baylor Research Institute Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
AU2015287833B2 (en) 2014-07-08 2018-09-13 The Children's Medical Center Corporation Compositions and methods for treating diabetes
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
US10052394B2 (en) 2014-11-21 2018-08-21 General Electric Company Microbubble tether for diagnostic and therapeutic applications
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
AU2019210204B2 (en) * 2018-01-18 2024-05-16 EndoProtech, Inc. Treating microvascular dysfunction
WO2020210458A1 (en) * 2019-04-12 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Pulsed focused ultrasound therapy for treatment of pancreatic disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
US7374390B2 (en) * 2001-05-25 2008-05-20 Integrated Vision, Inc. Lift mechanism for a seating device
CN101389273B (zh) * 2004-08-05 2012-09-05 贝勒研究院 基因或药物递送***
AU2007299649B2 (en) * 2006-09-22 2012-11-15 Baylor Research Institute In vivo transformation of pancreatic acinar cells into insulin-producing cells
US20080114287A1 (en) * 2006-11-14 2008-05-15 Kar Neng Lai Ultrasound Microbubble Mediated Genes Delivery System
AR076445A1 (es) * 2008-11-13 2011-06-15 Baylor Res Inst Regeneracion de islotes pancreaticos y reversion de la diabetes por medio de la administracion in vivo de genes del factor de transcripcion de los islotes. composicion. metodo. vector. celula.

Also Published As

Publication number Publication date
TW201139673A (en) 2011-11-16
US20110182979A1 (en) 2011-07-28
WO2011094352A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
AR080029A1 (es) Composicion de microburbujas que comprende un adn plasmidico que codifica un factor de crecimiento del endotelio vascular humano
Zhu et al. CCND2 overexpression enhances the regenerative potency of human induced pluripotent stem cell–derived cardiomyocytes: remuscularization of injured ventricle
US11371031B2 (en) CasZ compositions and methods of use
Turnbull et al. Myocardial delivery of lipidoid nanoparticle carrying modRNA induces rapid and transient expression
Kim et al. Hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells prevent myocardial ischemic injury
US11299749B2 (en) Cell-specific expression of modRNA
Matsumoto et al. Xenotransplanted embryonic kidney provides a niche for endogenous mesenchymal stem cell differentiation into erythropoietin-producing tissue
Elnakish et al. Mesenchymal stem cells for cardiac regeneration: translation to bedside reality
Lepperhof et al. Bioluminescent imaging of genetically selected induced pluripotent stem cell-derived cardiomyocytes after transplantation into infarcted heart of syngeneic recipients
Hakim et al. Emerging tools for erectile dysfunction: a role for regenerative medicine
Wang et al. miR-19a/19b-loaded exosomes in combination with mesenchymal stem cell transplantation in a preclinical model of myocardial infarction
AR076445A1 (es) Regeneracion de islotes pancreaticos y reversion de la diabetes por medio de la administracion in vivo de genes del factor de transcripcion de los islotes. composicion. metodo. vector. celula.
Citro et al. Directed self-assembly of a xenogeneic vascularized endocrine pancreas for type 1 diabetes
Hirayama et al. Local long-term expression of lentivirally delivered IL-10 in the lung attenuates obliteration of intrapulmonary allograft airways
US20080145937A1 (en) In Vivo Transformation of Pancreatic Acinar Cells into Insulin-Producing Cells
Sasaki et al. Subcutaneous transplantation of human embryonic stem cells-derived pituitary organoids
WO2022260764A2 (en) Engineered cells for producing of therapeutic agents to be delivered by a hybrid bioelectronic device
Harper et al. A18 BLINDED BY THE LIGHT: INSIGHT FROM GENETICS IN PAH: Bmpr2 Augmented Epc Delivery In A Rat Monocrotaline Induced Pah Model Alters Smad Signalling Profiles
Mohammad Dezashibi et al. Ectopic expression of insulin in a type 1 diabetic rat model by injection of manipulated mesenchymal stem cells with an insulin construct driven by a glucose‐sensitive promoter in the port vein
Al-Saadi et al. Endovascular transplantation of mRNA-enhanced mesenchymal stromal cells results in superior therapeutic protein expression in swine heart
Harper et al. Bmpr2 Augmented Epc Delivery In A Rat Monocrotaline Induced Pah Model Alters Smad Signalling Profiles
Gvazava et al. Compensatory function of submandibular gland in mice with streptozotocin diabetes under conditions of transplantation
Hanmei et al. Tumor microenvironment responsive dual-fluorescence" mother-baby" nano-delivery system for deep tumor penetration
JP2024522256A (ja) 免疫寛容を誘導するための合成タンパク質
Chen et al. Gaussia luciferase reporter assay for assessment of gene delivery systems in vivo

Legal Events

Date Code Title Description
FB Suspension of granting procedure